ArticleClinical ophthalmology (Auckland, N.Z.)2026
Visual Outcomes with Enhanced Monofocal and Non-Diffractive Extended Depth-of-Field Intraocular Lenses.
Article in Clinical ophthalmology (Auckland, N.Z.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To directly compare visual outcomes and quality of vision between an enhanced monofocal intraocular lens (IOL), a non-diffractive extended depth-of-field (EDOF) IOL, and a standard monofocal IOL. Methods: This single-center, cohort study included patients undergoing bilateral cataract surgery targeted for emmetropia. Groups were stratified by implanted IOL: RayOne EMV (enhanced monofocal), AcrySof IQ Vivity (EDOF), and RayOne Aspheric (standard monofocal control). Outcomes included monocular and binocular visual acuities at distance, intermediate (66 cm), and near (40 cm), defocus curves, contrast sensitivity, and patient-reported outcomes (PRSIQ, QoV) assessed >3 months postoperatively. Results: Corrected distance visual acuity was comparable across groups. The Vivity group demonstrated significantly better uncorrected and distance-corrected intermediate and near acuity compared to both EMV and monofocal groups (p<0.001). The EMV group showed significantly better intermediate acuity than the monofocal control (p<0.05) but no difference for near vision. The binocular functional depth of field (0.2 logMAR threshold) was 1.6 D for Vivity, 1.3 D for EMV, and 1.1 D for the monofocal control. Contrast sensitivity was significantly lower in the Vivity group compared to the EMV and monofocal groups (p<0.05). While Vivity achieved higher near-spectacle independence (31.8%), the EMV group reported significantly lower "bothersome" scores on the QoV questionnaire than both other groups. Conclusion: The Vivity IOL provided the broadest range of vision, extending efficacy into near tasks, but was associated with reduced contrast sensitivity. The RayOne EMV IOL effectively bridged the gap between standard monofocal and EDOF technologies, significantly improving intermediate vision while maintaining a monofocal-like contrast sensitivity and safety profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.